Acute myeloid leukemia induced by graded reduction of a lineage-specific transcription factor, PU.1.
The DOI matches its Crossref record; 28 of the 28 references it cites were found in a registry or an index.
Abstract
Transcription factors are believed to have a dominant role in acute myeloid leukemia (AML). This idea is supported by analysis of gene-knockout mice, which uncovered crucial roles of several transcription factors in normal hematopoiesis, and of individuals with leukemia, in whom transcription factors are frequently downregulated or mutated. However, analysis of knockout animals has not shown a direct link between abrogated transcription factors and the pathogenesis of AML. Sfpi1, encoding the lineage-specific transcription factor PU.1, is indispensable for normal myeloid and lymphoid development. We found that mice carrying hypomorphic Sfpi1 alleles that reduce PU.1 expression to 20% of normal levels, unlike mice carrying homo- or heterozygous deletions of Sfpi1, developed AML. Unlike complete or 50% loss, 80% loss of PU.1 induced a precancerous state characterized by accumulation of an abnormal precursor pool retaining responsiveness to G-CSF with disruption of M- and GM-CSF pathways. Malignant transformation was associated with a high frequency of clonal chromosomal changes. Retroviral restoration of PU.1 expression rescued myeloid differentiation of mutant progenitors and AML blasts. These results suggest that tightly graded reduction, rather than complete loss, of a lineage-indispensable transcription factor can induce AML.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“In preleukemic states (e.g., MDS), where PU.1 downregulation permits clonal expansion 33-35”
From USP7 sustains hematopoietic stem cell homeostasis partially via PU.1 stabilization (2026) · cites this paper as [33]
In the citing paper
“In mice, a decrease in Pu.1-mediated differentiation gene activation causes leukemia.22”
From RUNX1 regulates corepressor interactions of PU.1 (2011) · cites this paper as [22]
In the citing paper
“Studies in murine models of AML with decreased levels of PU.1 showed an elevated expression of c-Myc.28”
From USP22 deficiency leads to myeloid leukemia upon oncogenic Kras activation through a PU.1-dependent mechanism (2018) · cites this paper as [28]
In the citing paper
“A reduction in PU.1 expression and activity is commonly seen in mouse and human cases of AML.[28][29][30]”
From USP22 deficiency leads to myeloid leukemia upon oncogenic Kras activation through a PU.1-dependent mechanism (2018) · cites this paper as [28]
In the citing paper
“Although loss or near-complete loss of the hematopoietic transcription factor PU.1 induces acute myeloid leukemia (AML) in mice”
From Minimal PU.1 reduction induces a preleukemic state and promotes development of acute myeloid leukemia (2015) · cites this paper as [9]
19 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
A clonogenic common myeloid progenitor that gives rise to all myeloid lineages
Akashi, K., Traver, D., Miyamoto, T., & Weissman, I. L. (2000) · Nature · doi:10.1038/35004599 · Cited by 2,617 · cited 1×
“We could not separate mutant progenitors into distinct common myeloid progenitor, myeloid-erythroid progenitor and granulocyte-macrophage progenitor subpopulation”
BackgroundSelf-citationOkuda, T., van Deursen, J., Hiebert, S. W., Grosveld, G., & Downing, J. R. (1996) · Cell · doi:10.1016/s0092-8674(00)80986-1 · Cited by 1,856 · cited 1×
“Like mice deficient in other transcription factors implicated in human AM”
BackgroundThe c-myc oncogene driven by immunoglobulin enhancers induces lymphoid malignancy in transgenic mice
Adams, J. M., Harris, A. W., Pinkert, C. A., Corcoran, L. M., Alexander, W. S., Cory, S., Palmiter, R. D., & Brinster, R. L. (1985) · Nature · doi:10.1038/318533a0 · Cited by 1,779
Requirement of transcription factor PU.1 in the development of multiple hematopoietic lineages
Scott, E. W., Simon, M. C., Anastasi, J., & Singh, H. (1994) · Science · doi:10.1126/science.8079170 · Cited by 1,532
Schwenk, F., Baron, U., & Rajewsky, K. (1995) · Nucleic Acids Research · doi:10.1093/nar/23.24.5080 · Cited by 1,289 · cited 1×
“F331 Spleen 39,X,-Y[6]/40,idem,+15[2]/41,XY,+15[2]”
Targeted disruption of the PU.1 gene results in multiple hematopoietic abnormalities
McKercher, S. R., Torbett, B. E., Anderson, K. L., Henkel, G. W., Vestal, D. J., Baribault, H., Klemsz, M., Feeney, A. J., Wu, G. E., Paige, C. J., et al. (1996) · The EMBO Journal · doi:10.1002/j.1460-2075.1996.tb00949.x · Cited by 1,130
An Fgf8 mutant allelic series generated by Cre- and Flp-mediated recombination
Meyers, E. N., Lewandoski, M., & Martin, G. R. (1998) · Nature Genetics · doi:10.1038/ng0298-136 · Cited by 1,031 · cited 1×
“We released a FRT -PGK neo - FRT resistance cassette from pK-11 (ref”
MethodZhang, D.-E., Zhang, P., Wang, N.-D., Hetherington, C. J., Darlington, G. J., & Tenen, D. G. (1997) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.94.2.569 · Cited by 910 · cited 1×
“Like mice deficient in other transcription factors implicated in human AM”
BackgroundSelf-citationPabst, T., Mueller, B. U., Zhang, P., Radomska, H. S., Narravula, S., Schnittger, S., Behre, G., Hiddemann, W., & Tenen, D. G. (2001) · Nature Genetics · doi:10.1038/85820 · Cited by 901
Self-citationReversible Tumorigenesis by MYC in Hematopoietic Lineages
Felsher, D. W., & Bishop, J. M. (1999) · Molecular Cell · doi:10.1016/s1097-2765(00)80367-6 · Cited by 881
Research works printed but not linked: 2
- Iwasaki-Arai, J. et al. C/EBPα deficiency in hematopoiesis induces accumulation of non-malignant myeloblasts mimicking acute myelogenous leukemia. Blood 100, 61a (2002).
- Duprez, E. et al. PU.1 deficiency blocks the production of Common Myeloid and Common Lymphoid Progenitors in both adult and fetal liver myelopoiesis. Blood 100, 61a (2002).
Cited by
Items 201–300 of 518
Cortés-Lavaud, X., Landecho, M. F., Maicas, M., Urquiza, L., Merino, J., Moreno–Miralles, I., & Odero, M. D. (2015) · The Journal of Immunology · doi:10.4049/jimmunol.1401868 · Cited by 36
“Thirteen of the 15 cases re- ported with the p.Arg396Gln mutation developed a myeloid malignancy (Supplemental Table I), and mice carrying hypomorphic Spi1 alleles, which reduce Spi1 expression to 20% of normal levels, developed AML (25).”
BackgroundInfluentialMYBL2 is a sub-haploinsufficient tumor suppressor gene in myeloid malignancy
Heinrichs, S., Conover, L. F., Bueso-Ramos, C., Kilpivaara, O., Stevenson, K. E., Neuberg, D. S., Loh, M. L., Wu, W.-S., Rodig, S. J., Garcia‐Manero, G., et al. (2013) · eLife · doi:10.7554/elife.00825 · Cited by 39
“1 expression in the molecular pathogenesis of myeloid malignancies (Rosenbauer et al., 2004; Liu et al., 2007).”
Rimmelé, P., Kosmider, O., Mayeux, P., Moreau-Gachelin, F., & Guillouf, C. (2007) · Blood · doi:10.1182/blood-2006-03-006718 · Cited by 35
Myeloid lncRNA LOUP mediates opposing regulatory effects of RUNX1 and RUNX1-ETO in t(8;21) AML
Trinh, B. Q., Ummarino, S., Zhang, Y., Ebralidze, A. K., Bassal, M. A., Nguyen, T. M., Heller, G., Coffey, R., Tenen, D. E., van der Kouwe, E., et al. (2021) · Blood · doi:10.1182/blood.2020007920 · Cited by 38
Self-citationBCL11A promotes myeloid leukemogenesis by repressing PU.1 target genes
Sunami, Y., Yokoyama, T., Yoshino, S., Takahara, T., Yamazaki, Y., Harada, H., & Nakamura, T. (2021) · Blood Advances · doi:10.1182/bloodadvances.2021004558 · Cited by 37
“Next, to investigate the possible involvement of BCL11A in human AML, the expression of BCL11A , as well as of SPI1 , encoding PU.1, was examined using AML cell lines in vitro.”
Epigenetic Control of SPI1 Gene by CTCF and ISWI ATPase SMARCA5
Dluhošová, M., Čuřík, N., Vargova, J., Jonasova, A. T., Zikmund, T., & Stopka, T. (2014) · PLoS ONE · doi:10.1371/journal.pone.0087448 · Cited by 35
“1 dictate differentiation outcome [22] and if SPI1 transcription is downregulated by deletion of the URE it results in AML [13].”
BackgroundGreif, P. A., Tizazu, B., Krause, A., Kremmer, E., & Bohlander, S. K. (2007) · Oncogene · doi:10.1038/sj.onc.1210945 · Cited by 43
“For example, lowering the levels of the Ets transcription factor PU.1 to just 20% of normal levels will result in leukemia while the complete absence of PU.1 does not lead to the development of leukemia in knockout mice (Rosenbauer et al., 2004).”
BackgroundControl of Self‐Renewal and Differentiation of Hematopoietic Stem Cells: HOXB4 on the Threshold
Klump, H., Schiedlmeier, B., & Baum, C. (2005) · Annals of the New York Academy of Sciences · doi:10.1196/annals.1349.002 · Cited by 45
Domínguez‐Soto, Á., Puig‐Kröger, A., Vega, M. A., & Corbí, A. L. (2005) · Journal of Biological Chemistry · doi:10.1074/jbc.m503401200 · Cited by 39
Möröy, T., & Khandanpour, C. (2019) · Frontiers in Oncology · doi:10.3389/fonc.2019.00824 · Cited by 39
“Other subtypes, the so-called core binding factor AMLs (CBF-AML), typically feature t(8;21) or inv(16) translocations involving the RUNX1, RUNX1T1, and CBFB genes.”
BackgroundMDMX acts as a pervasive preleukemic-to-acute myeloid leukemia transition mechanism
Ueda, K., Kumari, R., Schwenger, E., Wheat, J. C., Bohorquez, O., Narayanagari, S.-R., Taylor, S. J., Carvajal, L. A., Pradhan, K., Bartholdy, B., et al. (2021) · Cancer Cell · doi:10.1016/j.ccell.2021.02.006 · Cited by 36
“1 compared to WT controls and develop AML at 4 to 8 months of age (Rosenbauer et al., 2004).”
BackgroundZarnegar, M. A., & Rothenberg, E. V. (2012) · Oncogene · doi:10.1038/onc.2011.597 · Cited by 38
Early aberrant DNA methylation events in a mouse model of acute myeloid leukemia
Sonnet, M., Claus, R., Becker, N., Zucknick, M., Petersen, J., Lipka, D. B., Oakes, C. C., Andrulis, M., Lier, A., Milsom, M. D., et al. (2014) · Genome Medicine · doi:10.1186/gm551 · Cited by 37
“1 hypomorphs that develop AML (or much less frequently T-cell lymphomas) after a latency of 3 to 8 months [21,22].”
BackgroundSelf-citationPU.1 acts as tumor suppressor for myeloma cells through direct transcriptional repression of IRF4
Ueno, N., Nishimura, N., Ueno, S., Endo, S., Tatetsu, H., Hirata, S., Hata, H., Matsuoka, M., Mitsuya, H., & Okuno, Y. (2017) · Oncogene · doi:10.1038/onc.2017.79 · Cited by 34
Self-citationTranscriptomic profiling identifies a PU.1 regulatory network in macrophages
Weigelt, K., Lichtinger, M., Rehli, M., & Langmann, T. (2009) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2009.01.067 · Cited by 33
Heterozygous deletion of the PU.1 locus in human AML
Bonadies, N., Pabst, T., & Mueller, B. U. (2010) · Blood · doi:10.1182/blood-2009-03-212225 · Cited by 33
The Regulatory Capacity of Bivalent Genes—A Theoretical Approach
Thalheim, T., Herberg, M., Loeffler, M., & Galle, J. (2017) · International Journal of Molecular Sciences · doi:10.3390/ijms18051069 · Cited by 34
“1 indeed is sufficient to induce AML in mice [52].”
BackgroundDeregulated transcription factors in leukemia
Shima, Y., & Kitabayashi, I. (2011) · International Journal of Hematology · doi:10.1007/s12185-011-0905-9 · Cited by 36
“deletion of the distal enhancer of Sfpi1, the gene encoding PU.1, causes a reduction of PU.1 expression and leads to the development of AML [ 93 ].”
BackgroundTranscriptional networks in acute myeloid leukemia
Thoms, J. A. I., Beck, D., & Pimanda, J. E. (2019) · Genes Chromosomes and Cancer · doi:10.1002/gcc.22794 · Cited by 34
Wang, X., Jin, P., Zhang, Y., & Wang, K. (2021) · Cell Death and Disease · doi:10.1038/s41419-021-03566-2 · Cited by 35
Aggressive acute myeloid leukemia in PU.1/p53 double-mutant mice
Bašová, P., Pospíšil, V., Savvulidi, F. G., Burda, P., Vargová, K., Staněk, L., Dluhošová, M., Kužmová, E., Jonasova, A. T., Steidl, U. G., et al. (2013) · Oncogene · doi:10.1038/onc.2013.414 · Cited by 37
Sox4 cooperates with PU.1 haploinsufficiency in murine myeloid leukemia
Aue, G., Du, Y., Cleveland, S. M., Smith, S. B., Davé, U. P., Liu, D., Weniger, M. A., Metais, J. Y., Jenkins, N. A., Copeland, N. G., et al. (2011) · Blood · doi:10.1182/blood-2011-04-351528 · Cited by 36
Yamamoto, R., Kawahara, M., Ito, S., Satoh, J., Tatsumi, G., Hishizawa, M., Suzuki, T., & Andoh, A. (2018) · Oncotarget · doi:10.18632/oncotarget.24774 · Cited by 33
Saito, S., Nouno, K., Shimizu, R., Yamamoto, M. P., & Nagata, K. (2007) · Journal of Cellular Physiology · doi:10.1002/jcp.21199 · Cited by 35
“It is also reported that the decrease of the expression level of transcription factors, PU.1 and GATA-1, generates leukemia in mouse model systems (Rosenbauer et al., 2004; Shimizu et al., 2004).”
BackgroundIskander, K. S., Barrios, R. J., & Jaiswal, A. K. (2008) · Cancer Research · doi:10.1158/0008-5472.can-08-0766 · Cited by 36
Senescence is a Spi1-induced anti-proliferative mechanism in primary hematopoietic cells
Delestré, L., Cui, H., Esposito, M., Quiveron, C., Mylonas, E., Penard-Lacronique, V., Bischof, O., & Guillouf, C. (2017) · Haematologica · doi:10.3324/haematol.2016.157636 · Cited by 32
PRDM16s transforms megakaryocyte-erythroid progenitors into myeloid leukemia–initiating cells
Hu, T., Morita, K., Hill, M. C., Jiang, Y., Kitano, A., Saito, Y., Wang, F., Mao, X., Hoegenauer, K. A., Morishita, K., et al. (2019) · Blood · doi:10.1182/blood.2018888255 · Cited by 33
Nicola, J. M. B. (2009) · Frontiers in bioscience · doi:10.2741/3333 · Cited by 39
Yang, Z., Kondo, T., Voorhorst, C. S., Nabinger, S. C., Ndong, L., Yin, F., Chan, E. M., Yu, M., Würstlin, O., Kratz, C. P., et al. (2009) · Molecular and Cellular Biology · doi:10.1128/mcb.01330-08 · Cited by 33
“1 expression and function in acute myeloid leukemia (48, 54, 64) as well as in chronic myelogenous leukemia (1).”
BackgroundThe role of MOZ/KAT6A in hematological malignancies and advances in MOZ/KAT6A inhibitors
Su, J., Wang, X., Bai, Y., Sun, M., Yao, Y., & Duan, Y. (2021) · Pharmacological Research · doi:10.1016/j.phrs.2021.105930 · Cited by 31
Implication of replicative stress-related stem cell ageing in radiation-induced murine leukaemia
Ban, N., & Kai, M. (2009) · British Journal of Cancer · doi:10.1038/sj.bjc.6605135 · Cited by 35
“…are often accompanied by additional genetic alterations, such as amplification of Myc (Rosenbauer et al, 2004; Hirouchi et al, 2008), studies with genetically engineered mice show that downregulation or inactivation of PU.1 is sufficient to induce AML (Rosenbauer et al, 2004; Metcalf et al, 2006).”
BackgroundLentiviral PU.1 overexpression restores differentiation in myeloid leukemic blasts
Durual, S., Rideau, A., Ruault-Jungblut, S., Cossali, D., Beris, P., Piguet, V, & Matthes, T. (2007) · Leukemia · doi:10.1038/sj.leu.2404645 · Cited by 30
Lam, C. F., Yeung, H. T., Lam, Y. M., & Ng, R. K. (2018) · Leukemia Research · doi:10.1016/j.leukres.2018.03.012 · Cited by 31
LSD1-mediated repression of GFI1 super-enhancer plays an essential role in erythroleukemia
Tatsumi, G., Kawahara, M., Yamamoto, R., Hishizawa, M., Kito, K., Suzuki, T., Takaori‐Kondo, A., & Andoh, A. (2019) · Leukemia · doi:10.1038/s41375-019-0614-6 · Cited by 30
Radiation-induced myeloid leukemia in murine models
Rivina, L., Davoren, M. J., & Schiestl, R. H. (2014) · Human Genomics · doi:10.1186/1479-7364-8-13 · Cited by 35
“1, leading to expression levels at about 20% of wild type, induces AML in mice inactivated from birth by 3–8 months of age [96].”
BackgroundXu, L., Sokalski, K. M., Hotke, K., Christie, D. A., Zarnett, O. J., Piskorz, J., Thillainadesan, G., Torchia, J., & DeKoter, R. P. (2012) · The Journal of Immunology · doi:10.4049/jimmunol.1201267 · Cited by 32
“1 caused by mutation or repression of the Sfpi1 gene are sufficient to induce acute myeloid leukemia (8, 44).”
BackgroundBurda, P., Curik, N., Kokavec, J., Basova, P., Mikulenkova, D., Skoultchi, A. I., Zavadil, J., & Stopka, T. (2009) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-09-0031 · Cited by 28
“1 levels below a certain threshold (∼20%) cause a block of hematopoietic differentiation accompanied with accelerated proliferation (8, 9).”
BackgroundMetallothionein-1 Isoforms and Vimentin Are Direct PU.1 Downstream Target Genes in Leukemia Cells
Imoto, A., Okada, M., Okazaki, T., Kitasato, H., Harigae, H., & Takahashi, S. (2010) · Journal of Biological Chemistry · doi:10.1074/jbc.m109.095810 · Cited by 33
A leukemia fusion protein attenuates the spindle checkpoint and promotes aneuploidy
Boyapati, A., Yan, M., Peterson, L. F., Biggs, J. R., Beau, M. M. L., & Zhang, D. (2006) · Blood · doi:10.1182/blood-2006-09-045583 · Cited by 34
PU.1 Activates Transcription of SHP-1 Gene in Hematopoietic Cells
Wlodarski, P., Zhang, Q., Liu, X., Kasprzycka, M., Marzec, M., & Wasik, M. A. (2007) · Journal of Biological Chemistry · doi:10.1074/jbc.m607526200 · Cited by 29
Unger, C. A., Kärner, E., Treschow, A., Stellan, B., Felldin, U., Concha, H., Wendel, M., Hovatta, O., Aints, A., Ährlund‐Richter, L., et al. (2008) · Stem Cells · doi:10.1634/stemcells.2007-0876 · Cited by 29
CITED2-mediated human hematopoietic stem cell maintenance is critical for acute myeloid leukemia
Korthuis, P. M., Berger, G., Bakker, B., Geugien, M., Jaques, J., de Haan, G., Schuringa, J. J., Vellenga, E., & Schepers, H. (2014) · Leukemia · doi:10.1038/leu.2014.259 · Cited by 34
Intrinsic disorder controls two functionally distinct dimers of the master transcription factor PU.1
Xhani, S., Lee, S., Kim, H. M., Wang, S., Esaki, S., Ha, V. L., Khanezarrin, M., Fernandez, G. L., Albrecht, A. V., Aramini, J. M., et al. (2020) · Science Advances · doi:10.1126/sciadv.aay3178 · Cited by 36
Systems biology of transcription control in macrophages
Ravasi, T., Wells, C. A., & Hume, D. A. (2007) · BioEssays · doi:10.1002/bies.20683 · Cited by 28
ZNF143 protein is an important regulator of the myeloid transcription factor C/EBPα
Gonzalez, D., Luyten, A., Bartholdy, B., Zhou, Q., Adamcova, M. K., Ebralidze, A. K., Swanson, K. D., Radomska, H. S., Zhang, P., Kobayashi, S. S., et al. (2017) · Journal of Biological Chemistry · doi:10.1074/jbc.m117.811109 · Cited by 33
Self-citationNtari, L., Σάκκου, Μ., Chouvardas, P., Mourouzis, I. S., Prados, A., Denis, M. C., Karagianni, N., Pantos, C. I., & Kollias, G. A. (2018) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2017-212597 · Cited by 32
Jansen, B., Sama, I. E., Eleveld-Trancikova, D., Hout-Kuijer, M. A. V., Jansen, J. H., Huynen, M. A., & Adema, G. J. (2011) · BMC Genomics · doi:10.1186/1471-2164-12-330 · Cited by 34
“1), which is indispensable for normal myeloid and lymphoid development [59] and specificity protein 1 (SP1), which is involved in the expression of dendritic cell-specific ICAM-3 grabbing non-integrin (DC-SIGN) [60].”
BackgroundBonifer, C., Hoogenkamp, M., Krysinska, H., & Tagoh, H. (2008) · Seminars in Immunology · doi:10.1016/j.smim.2008.05.001 · Cited by 27
The transcriptional regulation of normal and malignant blood cell development
Edginton‐White, B., & Bonifer, C. (2021) · FEBS Journal · doi:10.1111/febs.15735 · Cited by 28
Transcription factor GATA-1 and Down syndrome leukemogenesis
Muntean, A. G., Ge, Y., Taub, J. W., & Crispino, J. D. (2006) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.1080/10428190500485810 · Cited by 33
Hirouchi, T., Takabatake, T., Yoshida, K., Nitta, Y., Nakamura, M. M., Tanaka, S., Ichinohe, K., Oghiso, Y., & Tanaka, K. J. (2008) · Experimental Hematology · doi:10.1016/j.exphem.2008.01.015 · Cited by 30
Ski can negatively regulates macrophage differentiation through its interaction with PU.1
Ueki, N., Zhang, L., & Haymann, M. J. (2007) · Oncogene · doi:10.1038/sj.onc.1210654 · Cited by 29
“Most importantly, graded changes in each factor’s concentration could result in committing a hematopoietic progenitor cell fate (Dahl and Simon, 2003; Rosenbauer et al., 2004).”
Wilkinson, A. C., Kawata-Matsuura, V. K. S., Schütte, J., Gao, X., Antoniou, S., Baumann, C., Woodhouse, S., Hannah, R., Tanaka, Y., Swiers, G., et al. (2014) · Development · doi:10.1242/dev.115709 · Cited by 29
“Two well-studied examples of such haematopoietic cisregulatory elements are the PU.1-14kb (Rosenbauer et al., 2004; Okuno et al., 2005; Huang et al., 2008; Staber et al., 2013) and Scl +40kb (Delabesse et al., 2005; Ogilvy et al., 2007; Ferreira et al., 2013).”
InfluentialDevelopment and Regulatory Application of Microrna Biomarkers
Krauskopf, J., Verheijen, M. C. T., Kleinjans, J. C. S., de Kok, T. M. C. M., & Caiment, F. (2015) · Biomarkers in Medicine · doi:10.2217/bmm.15.50 · Cited by 28
Noguera, N. I., Piredda, M. L., Taulli, R., Catalano, G., Angelini, G., Gaur, G., Nervi, C., Voso, M. T., Lunardi, A., Pandolfi, P. P., et al. (2016) · Oncotarget · doi:10.18632/oncotarget.11964 · Cited by 27
“1 downregulation or suppression causes AML [19-21], suggesting its pivotal role as tumor suppressor gene also in acute leukemia.”
InfluentialSignatures of DNA target selectivity by ETS transcription factors
Poon, G. M. K., & Kim, H. M. (2017) · Transcription · doi:10.1080/21541264.2017.1302901 · Cited by 30
Modeling the Hematopoietic Landscape
Brown, G., & Ceredig, R. (2019) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2019.00104 · Cited by 27
Gain‐of‐Function Effects of N‐Terminal CEBPA Mutations in Acute Myeloid Leukemia
Schmidt, L., Heyes, E., & Grebien, F. (2020) · BioEssays · doi:10.1002/bies.201900178 · Cited by 26
Sood, R. B., & Liu, P. (2012) · Advances in Hematology · doi:10.1155/2012/830703 · Cited by 28
Wang, Y., Welc, S. S., Wehling‐Henricks, M., Kong, Y., Thomas, C., Montecino‐Rodriguez, E., Dorshkind, K. A., & Tidball, J. G. (2022) · Aging Cell · doi:10.1111/acel.13690 · Cited by 27
“…or hypomorphic alleles of Spi1 showed that ablating or decreasing Spi1 expression at different stages of myeloid lineage determination can cause several defects in myeloid cell development (DeKoter et al., 2007; Rosenbauer et al., 2004), although effects on macrophage phenotype are rarely reported.”
BackgroundStructural mechanism of synergistic targeting of the CX3CR1 nucleosome by PU.1 and C/EBPα
Lian, T., Guan, R., Zhou, B., & Bai, Y. (2024) · Nature Structural & Molecular Biology · doi:10.1038/s41594-023-01189-z · Cited by 28
“PU.1 mutation and reduced expression have been associated with acute myeloid leukemia (AML) and agam-maglobulinemia 17–19 .”
Borghesi, L. (2014) · The Journal of Immunology · doi:10.4049/jimmunol.1400936 · Cited by 30
“1 distal enhancer are mechanistically linked to acute myeloid leukemia (31, 62).”
BackgroundNDRG1 contributes to retinoic acid-induced differentiation of leukemic cells
Chen, S., Han, Y., Zheng, Y., Zhao, M. L., Yan, H., Zhao, Q. L., Chen, G., & Li, D. (2008) · Leukemia Research · doi:10.1016/j.leukres.2008.10.016 · Cited by 28
Distinct Roles for SCL in Erythroid Specification and Maturation in Zebrafish
Juarez, M. A., Su, F., Chun, S., Kiel, M. J., & Lyons, S. E. (2005) · Journal of Biological Chemistry · doi:10.1074/jbc.m507998200 · Cited by 27
Yang, H., Liang, H., Yan, J.-S., Tao, R., Hao, S., & Ma, L. (2012) · International Journal of Hematology · doi:10.1007/s12185-012-1106-x · Cited by 27
“H. Yang H. Liang R. Tao S. Hao L. Ma (&) Department of Hematology, Xin Hua Hospital, Affiliated to Shanghai Jiao Tong University (SJTU) School of Medicine, 1665 Kong Jiang Road, Shanghai 200092, China e-mail: docmly@gmail.com J. Yan Department of Hematology, The Second Affiliated Hospital of Dalian Medical University,…”
BackgroundInfluentialSoodgupta, D., White, L. S., Yang, W., Johnston, R., Andrews, J. M., Kohyama, M., MURPHY, K. M. M., Mosammaparast, N., Payton, J. E., & Bednarski, J. J. (2019) · Cell Reports · doi:10.1016/j.celrep.2019.09.026 · Cited by 27
PU.1 and Junb: suppressing the formation of acute myeloid leukemia stem cells.
Somervaille, T. C. P., & Cleary, M. L. (2006) · Cancer Cell · doi:10.1016/j.ccr.2006.11.009 · Cited by 25
Cofré, J., Menezes, J. R. L., Pizzatti, L., & Abdelhay, E. S. F. W. (2012) · Cancer Cell International · doi:10.1186/1475-2867-12-28 · Cited by 27
Zhang, Z., Wu, E., Qian, Z., & Wu, W.-S. (2014) · Scientific Reports · doi:10.1038/srep07338 · Cited by 28
Anguita, E., Gupta, R., Olariu, V., Valk, P. J. M., Peterson, C., Delwel, R., & Enver, T. (2016) · Developmental Biology · doi:10.1016/j.ydbio.2016.02.002 · Cited by 26
Molecular functions of SIRPα and its role in cancer (Review)
Takahashi, S. (2018) · Biomedical Reports · doi:10.3892/br.2018.1102 · Cited by 32
“As downregulation of PU.1 induces AML development (40,41), suppression of SIRP α 1 expression induced by PU.1 downregulation may serve a role in the pathogenesis of AML.”
RUNX1-ETO: Attacking the Epigenome for Genomic Instable Leukemia
van der Kouwe, E., & Staber, P. B. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20020350 · Cited by 29
“1 levels but also induces leukemia [159].”
Suppression of Pu.1 function results in expanded myelopoiesis in zebrafish
Sun, J., Liu, W., Li, L., Chen, J., Wu, M., Zhang, Y., Leung, A. Y. H., Zhang, W., Wen, Z., & Liao, W. (2013) · Leukemia · doi:10.1038/leu.2013.67 · Cited by 24
Zikmund, T., Paszeková, H., Kokavec, J., Kerbs, P., Thakur, S., Turková, T., Tauchmanová, P., Greif, P. A., & Stopka, T. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21062073 · Cited by 24
“1 gene [7] that represents key hematopoietic transcription factor and dose-dependent leukemia suppressor [20].”
BackgroundChromatin Dynamics in Lineage Commitment and Cellular Reprogramming
Shchuka, V. M., Malek-Gilani, N., Singh, G., Langroudi, L., Dhaliwal, N. K., Moorthy, S. D., Davidson, S., Macpherson, N. N., & Mitchell, J. A. (2015) · Genes · doi:10.3390/genes6030641 · Cited by 24
Burda, P., Vargova, J., Čuřík, N., Šálek, C., Papadopoulos, G. L., Strouboulis, J., & Stopka, T. (2016) · PLoS ONE · doi:10.1371/journal.pone.0152234 · Cited by 27
“1 expression imposed by the integrated SFFV provirus at mURE [1].”
Willcockson, M. A., Taylor, S. J., Ghosh, S., Healton, S. E., Wheat, J. C., Wilson, T. J., Steidl, U. G., & Skoultchi, A. I. (2019) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1901122116 · Cited by 26
“1 mRNA levels, we used a mouse strain lacking the URE (14).”
BackgroundMethodStage-specific action of Runx1 and GATA3 controls silencing of PU.1 expression in mouse pro–T cells
Hosokawa, H., Koizumi, M., Masuhara, K., Romero-Wolf, M., Tanaka, T., Nakayama, T., & Rothenberg, E. V. (2021) · The Journal of Experimental Medicine · doi:10.1084/jem.20202648 · Cited by 24
Zhang, L., & Friedman, A. D. (2011) · Blood · doi:10.1182/blood-2011-01-331157 · Cited by 24
Aivalioti, M. M., Bartholdy, B. A., Pradhan, K., Bhagat, T. D., Zintiridou, A., Jeong, J. J., Thiruthuvanathan, V. J., Pujato, M., Paranjpe, A., Zhang, C., et al. (2022) · Blood Cancer Discovery · doi:10.1158/2643-3230.bcd-21-0226 · Cited by 22
“org cells (25) have no overt hematologic defects in steady state, which had been in stark contrast to the observed minimal to moderate PU.”
BackgroundResultInfluentialSolomon, L. A., Podder, S., He, J., Jackson-Chornenki, N. L., Gibson, K., Ziliotto, R. G., Rhee, J., & DeKoter, R. P. (2017) · Molecular and Cellular Biology · doi:10.1128/mcb.00013-17 · Cited by 22
Attenuation of AML1-ETO cellular dysregulation correlates with increased leukemogenic potential
DeKelver, R. C., Yan, M., Ahn, E.-Y. E., Shia, W.-J., Speck, N. A., & Zhang, D. (2013) · Blood · doi:10.1182/blood-2012-11-465641 · Cited by 22
“1 expression developed a precancerous state predisposing them to leukemia.(22) Similarly, histone acetyltransferase mutations correlated with leukemia and lymphoma development were usually monoallelic or otherwise did not completely block HAT function, indicating that decreased dosage or attenuated function is suffici…”
Hyde, R. K., & Liu, P. (2010) · Journal of Cellular Biochemistry · doi:10.1002/jcb.22596 · Cited by 23
“Of note PU.1 contribution to leukemogenesis is similarly dose dependent; mice carrying hypomorphic alleles of Pu.1 with reduced expression (20% of normal) developed AML rapidly and efficiently, while mice with homo- or heterozygous deletion of Pu.1 did not develop leukemia [Rosenbauer et al., 2004].”
BackgroundRegalo, G., & Leutz, A. (2013) · EMBO Molecular Medicine · doi:10.1002/emmm.201302834 · Cited by 25
“Interestingly, experimental reduction of PU.1 in myeloid cells incites their leukaemic conversion (Rosenbauer et al, 2004).”
Hematopoietic Stem Cell Molecular Targets and Factors Essential for Hematopoiesis
Raghav, P. K., & Gangenahalli, G. U. (2018) · Journal of Stem Cell Research & Therapy · doi:10.4172/2157-7633.1000441 · Cited by 25
“1 or GATA1 activity leads to leukemogenesis [57-60].”
BackgroundInverse correlation between Flt3 and PU.1 expression in acute myeloblastic leukemias
Inomata, M., Takahashi, S., Harigae, H., Kameoka, J., Kaku, M., & Sasaki, T. (2005) · Leukemia Research · doi:10.1016/j.leukres.2005.07.015 · Cited by 27
Emerging Flt3 kinase inhibitors in the treatment of leukaemia
Tickenbrock, L., Müller‐Tidow, C., Berdel, W. E., & Serve, H. L. (2006) · Expert Opinion on Emerging Drugs · doi:10.1517/14728214.11.1.153 · Cited by 22
“Imbalanced expression or impairment of function of these transcription factors by mutations results in blocks of myeloid differentiation [68,69].”
BackgroundPapetti, M., & Skoultchi, A. I. (2007) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-07-0145 · Cited by 26
“1 in mice has been associated with the development of leukemia in myeloid cells (44, 45), and heterozygous mutations in PU.”
BackgroundUchiumi, F., Sakakibara, G., Sato, J., & Tanuma, S.-I. (2008) · Genes to Cells · doi:10.1111/j.1365-2443.2008.01240.x · Cited by 22
“PU.1, which is also known as Spi-1 (Ray et al. 1990), regulates myeloid lineage commitment (Nerlov & Graf 1998), and it was reported that AML is induced by graded reduction of PU.1 ( Rosenbauer et al. 2004 ).”
BackgroundThe significance of low PU.1 expression in patients with acute promyelocytic leukemia
Zhu, X., Zhang, H., Qian, M., Zhao, X., Yang, W., Wang, P., Zhang, J., & Wang, K. (2012) · Journal of Hematology & Oncology · doi:10.1186/1756-8722-5-22 · Cited by 21
“1 or a graded reduction in its expression blocks myelomonocytic differentiation or maturation, resulting in the accumulation of myeloid blasts and, thus, the genesis of myelogenous leukemia [17,18].”
BackgroundMorita, K., Maeda, S., Suzuki, K., Kiyose, H., Taniguchi, J., Liu, P. P., Sugiyama, H., Adachi, S., & Kamikubo, Y. (2017) · Blood Advances · doi:10.1182/bloodadvances.2017007591 · Cited by 21
Role of tissue-specific AT-rich DNA sequence-binding proteins in lymphocyte differentiation
Yokota, T., & Kanakura, Y. (2014) · International Journal of Hematology · doi:10.1007/s12185-014-1602-2 · Cited by 21
Hou, Y., Sheng, Z., Mao, X., Li, C., Chen, J., Zhang, J., Huang, H., Ruan, H., Luo, L., & Li, L. (2016) · Scientific Reports · doi:10.1038/srep36853 · Cited by 22
PU.1: An ETS Family Transcription Factor That Regulates Leukemogenesis Besides Normal Hematopoiesis
Gupta, P., Gangenahalli, G. U., Verma, Y. K., Kishore, V., Gulati, S., Sharma, R. K., Chandra, R., & Saluja, D. (2006) · Stem Cells and Development · doi:10.1089/scd.2006.15.609 · Cited by 21
“Thus, reduced expression of PU.1 promotes recurring chromosomal changes, creating a secondary event that re-sults in the subsequent outgrowth of leukemic cells (40).”
InfluentialPU.1 induces apoptosis in myeloma cells through direct transactivation of TRAIL.
Ueno, S., Tatetsu, H., Hata, H., Iino, T., Niiro, H., Akashi, K., Tenen, D. G., Mitsuya, H., & Okuno, Y. (2009) · Oncogene · doi:10.1038/onc.2009.263 · Cited by 20
“Moreover, conditional knockout of this 14-kb 50-upstream region led to downregulation of PU.1 to 20% of wild-type mice, and all of these mice developed acute myeloid leukemia (Rosenbauer et al., 2004).”
BackgroundSelf-citationThillo, Q. V., Bie, J. D., Seneviratne, J. A., Demeyer, S., Omari, S. A., Balachandran, A., Zhai, V., Tam, W. L., Sweron, B., Geerdens, E., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-24442-9 · Cited by 21
High expression of PU.1 is associated with Her‑2 and shorter survival in patients with breast cancer
Lin, J., Liu, W., Luan, T., Yuan, L., Jiang, W., Cai, H., Yuan, W., Wang, Y., Zhang, Q., & Wang, L. (2017) · Oncology Letters · doi:10.3892/ol.2017.7204 · Cited by 26
Ultimate Precision: Targeting Cancer but Not Normal Self-replication
Velcheti, V., Schrump, D. S., & Saunthararajah, Y. (2018) · American Society of Clinical Oncology Educational Book · doi:10.1200/edbk_199753 · Cited by 23
Steinauer, N., Guo, C. H., & Zhang, J. (2020) · Journal of Biological Chemistry · doi:10.1074/jbc.ra120.013042 · Cited by 27
“functions in myeloid differentiation, including the 14 kb SPI1 URE (upstream regulatory element), of which heterozygous deletion is sufficient to cause AML in mice (4), and the +34/+42 kb CEBPA enhancers, which drive neutrophil- and monocytespecific CEBPA expression (26).”
BackgroundA two-mutation model of radiation-induced acute myeloid leukemia using historical mouse data
Dekkers, F., Bijwaard, H., Bouffler, S. D., Ellender, M., Huiskamp, R., Kowalczuk, C. I., Meijne, E. I. M., & Sutmuller, M. (2010) · Radiation and Environmental Biophysics · doi:10.1007/s00411-010-0328-7 · Cited by 23
“and Moreau-Gachelin 2006) or downregulation (Rosenbauer et al. 2004) of PU.”
Background
Metadata
- Authors
- Rosenbauer, F., Wagner, K., Kutok, J. L., Iwasaki, H., Le Beau, M. M., Okuno, Y., Akashi, K., Fiering, S., & Tenen, D. G.
- Affiliations
- Harvard University (US)
- Brigham and Women's Hospital (US)
- Dartmouth College (US)
- Corresponding author
- Tenen, Daniel G
- ORCID
- Venue
- Nature Genetics
- Published
- 2004-05-16
- Volume
- 36
- Issue
- 6
- Pages
- 624-630
- ISSN
- 1061-4036 (ISSN-L)
- 1546-1718
- OpenAlex
- W2060618743
- Cited by
- 506
- References
- 28
- Citations by year
- 2026: 8 · 2025: 8 · 2024: 11 · 2023: 21 · 2022: 10 · 2021: 25 · 2020: 13 · 2019: 22 · 2018: 25 · 2017: 24 · 2016: 19 · 2015: 18 · 2014: 27 · 2013: 36 · 2012: 28
- FWCI
- 20.73
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature Genetics (publishedVersion)
- PubMed (publishedVersion)
- MDC Repository (Max-Delbrueck-Center for Molecular Medicine) (submittedVersion)
- Funders
- Dartmouth College
- Deutsche Forschungsgemeinschaft
- National Institutes of Health
- National Cancer Institute (P30CA023108)
- Topics
- Health Sciences › Medicine › Hematology › Acute Myeloid Leukemia Research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Retinoids in leukemia and cellular processes
- Health Sciences › Medicine › Hematology › Hematopoietic Stem Cell Transplantation
- Keywords
- acute myeloid leukemia, PU.1, transcription factors, hypomorphic allele, myeloid development, myeloid differentiation, leukemogenesis
- MeSH terms
- Proto-Oncogene Protein Spi-1, Animals, Bone Marrow, Hematopoiesis, Humans, Karyotyping, Mice, Inbred C57BL, Mice, Mutant Strains, Mice, Transgenic, Proto-Oncogene Proteins, Spleen, Leukemia, Myeloid, Acute, Trans-Activators, Mice, Knockout, Mice
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.